Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Toxic soluble amyloid oligomers adopting an α–sheet conformation represent a structurally distinct class of pathogenic aggregates central to neurodegenerative disease mechanisms. These small, non-fibrillar aggregates of amyloidogenic proteins form early in amyloidosis and are highly toxic, strongly implicated as the primary pathogenic species in diseases like Alzheimer's. The α-sheet is a distinct protein secondary structure featuring alternating backbone dihedral angles, resulting in an extended sheet-like arrangement with unique hydrogen bonding patterns. Targeting this α-sheet conformation with de novo designed peptides offers a promising strategy for broad-spectrum inhibition across different amyloid diseases.
Inhibition of aggregation, neutralization of toxicity
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Toxic soluble amyloid oligomer (α-sheet conformation).